Articles by Louis Garguilo

31. 3 Questions Of Risk And Communication In A Time Of Coronavirus 3/20/2020

    Communication with your service providers may turn out most important in getting through immediate coronavirus-induced supply-chain challenges. Outsourcing may have got you into this situation; now it may be the only thing that can get you out. 

32. Sign It, President Trump; Don't Go There, President Xi 3/17/2020

    If drugs are discovered as purposefully held up by China to create a supply issue in the U.S., would you ever again employ a China-based CMO? Who would have thought Outsourced Pharma readers would be front and center in presidential politics? But you are.

33. Don't Spread The Wrong Message: COVID-19 And Respect For CMOs 3/13/2020

    The first was to be a celebration for safely, reliably, and productively keeping drug development and manufacturing supply chains running. The second is a threat to shut those supply chains down. But here’s a second irony: This new coronavirus may have provided us an opportunity of sorts. 

34. COVID-19 No-Fly Zone: A Year And Counting For Biopharma Supply Chains 3/4/2020

    “Right now, the coronavirus situation is more about transportation than manufacture,” says one biopharma executive with a global supply chain. “If this continues for more than a year, then I think it'll be getting products manufactured that will really be in play.”

35. Will We Learn The Right Lessons From The Coronavirus Crisis? 2/18/2020

    What happens – or continues not to happen – next with the coronavirus is critical to the future of global pharmaceutical development and manufacturing industry’s supply chains. But what lessons will we draw from the crisis?

36. Coronavirus: Pharma To The Rescue Too Simple 2/3/2020

    We may think we’ve been through this before with other coronaviruses such as SARS and MERS … but this time it feels different, like a larger confluence of too many overlapping and unstable tectonic plates.

37. Biotechs Will Make Music In The “Twenty-Twenties” 11/27/2019

    Outsourced Pharma Chief Editor Louis Garguilo talks with two biotech CEOs about why they believe this industry should expect an infusion of technology and improved productivity in the coming years.

38. Congressional Testimony: Stop Targeting U.S.-Based API Manufacturers 11/11/2019

    A representative for U.S.-based CDMOs recently testified before Congress regarding the fact 80% of our API is manufactured overseas. If you ask me, they picked the right guy to hear from. Here’s some “supplemental testimony” you’ll want to hear from Edward Price, President & CEO, SEQENS N.A.

39. Women In Our Workforce: A Biogen Millennial Manages CMOs 11/7/2019

    Tara Caiano, Virtual Plant Manager, Biogen is a young-woman professional. We featured her a few weeks ago, just after she had relocated from Biogen’s Boston location to manage an external supply-chain partner in Switzerland. She also spoke to me about some of her personal experiences. 

40. Are We Comfortable With “Patent-Cliff Innovation”? 9/20/2019

    Did you see where they took away the patents for the iPhone from Apple, and the patents for Toyota’s top car models? Of course you didn't — that’s ludicrous. So why is it normal to take away patents, and by extension products, from innovative drug companies? An essay on “patent cliff innovation."